Volume 369, Issue 9563, Pages (March 2007)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 370, Issue 9586, Pages (August 2007)

Enhanced performance feedback and patient participation to improve hand hygiene compliance of health-care workers in the setting of established multimodal.

Volume 357, Issue 9273, Pages (June 2001)

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.

Volume 357, Issue 9257, Pages (March 2001)

Volume 359, Issue 9322, Pages (June 2002)

Pharmacogenetics and future drug development and delivery

Volume 349, Issue 9057, Pages (April 1997)

Volume 11, Issue 4, Pages (April 2012)

Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and.

Volume 376, Issue 9734, Pages (July 2010)

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD.

Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in.

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 5, Issue 4, Pages (April 2006)

Intraoperative radiotherapy for early breast cancer

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 366, Issue 9482, Pages (July 2005)

Volume 13, Issue 3, Pages (March 2012)

Volume 14, Issue 3, Pages (March 2013)

Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial

One more reason to fund the Global Fund

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax.

Volume 12, Issue 9, Pages (September 2013)

Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study Dr R McGready,

Volume 373, Issue 9677, Pages (May 2009)

Aspirin in the prevention of cancer – Author's reply

How to Contain Artemisinin- and Multidrug-Resistant Falciparum Malaria

Volume 379, Issue 9816, Pages (February 2012)

Volume 9, Issue 9, Pages (September 2008)

Volume 366, Issue 9482, Pages (July 2005)

Volume 373, Issue 9663, Pages (February 2009)

AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised,

Volume 9, Issue 10, Pages (October 2008)

Volume 375, Issue 9732, Pages (June 2010)

Volume 379, Issue 9821, Pages (March 2012)

Volume 381, Issue 9875, Pages (April 2013)

Volume 390, Issue 10094, Pages (August 2017)

Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta- analysis Prof Ric N Price, MD, Lorenz von Seidlein, PhD, Neena.

Volume 379, Issue 9812, Pages (January 2012)

Volume 15, Issue 1, Pages (January 2014)

PATHWAY-2: spironolactone for resistant hypertension – Authors' reply

Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double- blind, parallel-group, placebo-controlled trial Dr Andrew R Goudie,

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled.

Volume 373, Issue 9660, Pages (January 2009)

Volume 9, Issue 9, Pages (September 2008)

Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis Robert J Commons, FRACP, Prof Julie.

Volume 388, Issue 10056, Pages (October 2016)

Volume 375, Issue 9709, Pages (January 2010)

Volume 372, Issue 9647, Pages (October 2008)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 371, Issue 9627, Pages (May 2008)

Department of Error The Lancet Volume 369, Issue 9564, (March 2007)

Volume 373, Issue 9658, Pages (January 2009)

Volume 375, Issue 9719, Pages (March 2010)

Volume 375, Issue 9714, Pages (February 2010)

Volume 361, Issue 9352, Pages (January 2003)

Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin.

Effect of standard dose paracetamol versus placebo as antipyretic therapy on liver injury in adult dengue infection: a multicentre randomised controlled.

Volume 11, Issue 3, Pages (March 2010)

Volume 11, Issue 1, Pages (January 2010)

Volume 373, Issue 9672, Pages (April 2009)

Volume 371, Issue 9618, Pages (March 2008)

Volume 393, Issue 10177, Pages (March 2019)

Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and.

Volume 378, Issue 9799, Pages (October 2011)

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Volume 371, Issue 9611, Pages (February 2008)

Presentation transcript:

Volume 369, Issue 9563, Pages 757-765 (March 2007) Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison A Ratcliff, FRACP, H Siswantoro, MD, E Kenangalem, MD, R Maristela, MD, RM Wuwung, F Laihad, MD, EP Ebsworth, MPH, Prof NM Anstey, FRACP, E Tjitra, MD, Dr RN Price, FRCP The Lancet Volume 369, Issue 9563, Pages 757-765 (March 2007) DOI: 10.1016/S0140-6736(07)60160-3 Copyright © 2007 Elsevier Ltd Terms and Conditions

Figure 1 Trial Profile *Maximum of 5 patients enrolled per clinic each day. †WHO criteria or recurrent vomiting or adverse event warranting rescue therapy. The Lancet 2007 369, 757-765DOI: (10.1016/S0140-6736(07)60160-3) Copyright © 2007 Elsevier Ltd Terms and Conditions

Figure 2 Cumulative risk of patients failing with P falciparum (upper) and P vivax (lower) parasitaemia (alone or mixed) Overall difference between treatment groups at day 42, after stratifying for the initial species of infection, for P falciparum, p=0·186; for P vivax, p<0·0001. The Lancet 2007 369, 757-765DOI: (10.1016/S0140-6736(07)60160-3) Copyright © 2007 Elsevier Ltd Terms and Conditions

Figure 3 P vivax gametocyte carriage in all patients studied after treatment with artemether-lumefantrine or dihydroartemisinin-piperaquine. The Lancet 2007 369, 757-765DOI: (10.1016/S0140-6736(07)60160-3) Copyright © 2007 Elsevier Ltd Terms and Conditions

Figure 4 Haematological recovery after treatment for patients receiving dihydroartemisinin-piperaquine and artemether-lumefantrine Error bars=95% CIs. The Lancet 2007 369, 757-765DOI: (10.1016/S0140-6736(07)60160-3) Copyright © 2007 Elsevier Ltd Terms and Conditions

Figure 5 Adverse events on day 1 or 2 in patients without symptoms on admission *p=0·003. The Lancet 2007 369, 757-765DOI: (10.1016/S0140-6736(07)60160-3) Copyright © 2007 Elsevier Ltd Terms and Conditions